James R. Berenson, MD

Articles

Dr. Berenson Discusses Results from the CHAMPION-1 Trial

June 6th 2014

James R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

Dr. Berenson on Weekly Carfilzomib For Patients With R/R Multiple Myeloma

May 9th 2014

James R. Berenson, MD, discusses a phase I study presented at the 2013 ASH meeting that analyzed the use weekly carfilzomib for patients with R/R multiple myeloma.

Dr. Berenson on a Study of Pomalidomide in R/R Myeloma

December 13th 2013

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

Dr. Berenson Discusses New Potential Targets in Myeloma

April 4th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, comments on new potential targets in myeloma.

Dr. Berenson on Carfilzomib in Refractory Multiple Myeloma

March 15th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

Dr. Berenson on Pomalidomide Plus Doxil in Multiple Myeloma

February 6th 2013

James R. Berenson, MD, discusses a phase I/II study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma.

Dr. Berenson on Zometa as the Gold Standard for Myeloma

February 9th 2012

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM

Dr. Berenson Discusses Early Phase Proteasome Inhibitors

January 24th 2012

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

Dr. Berenson Discusses the Carfilzomib Toxicity Profile

November 18th 2011

Dr. James Berenson from the Institute for Myeloma & Bone Cancer Research Discusses the Carfilzomib Toxicity Profile

Dr. Berenson on Carfilzomib for Multiple Myeloma

November 10th 2011

Dr. James Berenson from the Institute for Myeloma and Bone Cancer Research Discusses the Proteasome Inhibitor Carfilzomib

Dr. Berenson on the Study of Zometa in Multiple Myeloma

March 15th 2011

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.